TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16359878

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ankle/brachial index after exercise
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: NIRS
Number of subjects: 65
Study: 15199363

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (AAM) 12 grams/day for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (AAM)
Number of subjects: 65
Study: 11521934

Group type: EXPERIMENTAL
Intervention: New method of manipulative reduction, immobilisation and fixation using a U‐shaped plaster with the elbow in extension.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional method of reduction and immobilisation in a plaster slab with the elbow in flexion.
Number of subjects: 95
Study: 9850268

Group type: EXPERIMENTAL
Intervention: Intraoperative MMC (0.2 mg/ml for 3 min) with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard trabeculectomy with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraoperative MMC + post-operative 5-FU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraoperative MMC without post-operative 5-FU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No intraoperative MMC + post-operative 5-FU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Only trabeculectomy
Number of subjects: 60
Study: 8124697

Group type: EXPERIMENTAL
Intervention: 70% xylitol chewing gum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 35% xylitol + 35% sorbitol chewing gum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 17.5% xylitol + 52.5% sorbitol chewing gum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 70% sorbitol chewing gum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10% sorbitol mouthrinse
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10% sucrose mouthrinse
Number of subjects: 17
Study: 2664728

Group type: EXPERIMENTAL
Intervention: Meclofenomate 100 mg t.i.d. for 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 923067

Group type: EXPERIMENTAL
Intervention: Tocainide (400-600 mg loading doses, maintenance doses every 12 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tocainide (400 to 1100 mg every 12 hours during cross-over)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (during cross-over)
Number of subjects: 12
Study: 29315019

Group type: EXPERIMENTAL
Intervention: Daily almond intake (56 g per day for 20 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric control food
Number of subjects: 0
Study: 26237936

Group type: EXPERIMENTAL
Intervention: Soladey-3 titanium dioxide semiconductor toothbrush
Number of subjects: 71

Group type: COMPARATOR
Intervention: Inactive control device (toothbrush with inert resin core)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both active and control treatments
Number of subjects: 71
Study: 22322991

Group type: EXPERIMENTAL
Intervention: Play-integrated preparatory programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 21549637

Group type: EXPERIMENTAL
Intervention: Active HF-rTMS session
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 20
Study: 18452255

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.05 microg/kg/min for 2 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg/kg/hr)
Number of subjects: 56
Study: 17041823

Group type: EXPERIMENTAL
Intervention: Imitative treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment
Number of subjects: 14
Study: 12848585

Group type: EXPERIMENTAL
Intervention: BIA 3‐202 10-800mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIA 3‐202 400mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIA 3‐202
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10841825

Group type: EXPERIMENTAL
Intervention: Combined treatment with buserelin and tamoxifen
Number of subjects: 161

Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 161
Study: 9335367

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass system
Number of subjects: 31

Group type: COMPARATOR
Intervention: Noncoated cardiopulmonary bypass system
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 8076058

Group type: EXPERIMENTAL
Intervention: Leucocyte depletion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (undepleted leucocytes)
Number of subjects: 26
Study: 3026017

Group type: EXPERIMENTAL
Intervention: Sulbactam plus ampicillin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Metronidazole plus cefotaxime
Number of subjects: 73
Study: 30103761

Group type: EXPERIMENTAL
Intervention: Low-dose, high-frequency plus mobile mentoring (LDHF)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional group-based training (TRAD)
Number of subjects: 300
Study: 26763172

Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no range of motion exercises)
Number of subjects: 94
Study: 24240061

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise with ultrasound and microcurrent therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Therapeutic exercise with ultrasound alone
Number of subjects: 20
Study: 24614995

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU weekly
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21191362

Group type: EXPERIMENTAL
Intervention: High-protein (HP) formula
Number of subjects: 601

Group type: COMPARATOR
Intervention: Low-protein (LP) formula
Number of subjects: 601

Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 601
Study: 18701603

Group type: EXPERIMENTAL
Intervention: Atropine and Isoproterenol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Abnormal response to Atropine (Group B)
Number of subjects: 100
Study: 16679823

Group type: EXPERIMENTAL
Intervention: Glycerol-based hydration cream
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 26
Study: 14607581

Group type: EXPERIMENTAL
Intervention: CEE 0.625/MPA 2.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 2.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 1.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE 0.3/MPA 1.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CEE-alone groups
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 11068483

Group type: EXPERIMENTAL
Intervention: I‐T4
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8817007

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (ABP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional blood pressure (CBP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: ABP group
Number of subjects: 207

Group type: COMPARATOR
Intervention: CBP group
Number of subjects: 207
Study: 1576849

Group type: EXPERIMENTAL
Intervention: High work rate training (45 min/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low work rate training (proportionally longer time)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of high vs low work rate training
Number of subjects: 19
Study: 3329079

Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 299

Group type: COMPARATOR
Intervention: Norinyl 1/50
Number of subjects: 299
Study: 31663816

Group type: EXPERIMENTAL
Intervention: Anabolic androgen steroids (AS) users
Number of subjects: 181

Group type: COMPARATOR
Intervention: Non-anabolic androgen steroids (AS) users
Number of subjects: 181
Study: 29929030

Group type: EXPERIMENTAL
Intervention: Group 1 (≥3 mm spondylolisthesis difference between F/E radiographs)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group 2 (≥3 mm spondylolisthesis difference between U/S imaging)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Group 1 and Group 2 (comparison)
Number of subjects: 77
Study: 27450744

Group type: EXPERIMENTAL
Intervention: Active high frequency (theta patterned) rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 25424122

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 1053
Study: 22883632

Group type: EXPERIMENTAL
Intervention: TF-TAVR using first-generation Edwards-Sapien valves and delivery systems via a 22- or 24-F sheath
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: TF-TAVR
Number of subjects: 419
Study: 20456103

Group type: EXPERIMENTAL
Intervention: Repetitive hand hygiene
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (non-wet workers)
Number of subjects: 23
Study: 18639533

Group type: EXPERIMENTAL
Intervention: Explicit anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit anxiety
Number of subjects: 0
Study: 16647514

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC‐MPS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 90
Study: 12823676

Group type: EXPERIMENTAL
Intervention: Empirical treatment using agents for inflammatory bowel disease
Number of subjects: 0
Study: 10418645

Group type: EXPERIMENTAL
Intervention: Fentanyl (7 micrograms/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg)
Number of subjects: 60
Study: 7767058

Group type: EXPERIMENTAL
Intervention: TCM-WM
Number of subjects: 62

Group type: COMPARATOR
Intervention: WM
Number of subjects: 62
Study: 1968354

Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: sulphasalazine (subgroup with ESR > 20 mm/h)
Number of subjects: 62
Study: 631039

Group type: EXPERIMENTAL
Intervention: Oral doses of Ro 10-9359 (initial dose 1.0 mg/kg body-weight daily, reduced to 25-50 mg daily)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Classical local dithranol application
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Both oral Ro 10-9359 and local dithranol application
Number of subjects: 291
Study: 31766250

Group type: EXPERIMENTAL
Intervention: Low-dose iron MNP (5.0 mg iron)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Standard MNP (12.5 mg iron)
Number of subjects: 327
Study: 28947039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16590

Group type: COMPARATOR
Intervention: Fluticasone furoate 100 μg (FF)
Number of subjects: 16590

Group type: COMPARATOR
Intervention: Vilanterol 25 μg (VI)
Number of subjects: 16590

Group type: COMPARATOR
Intervention: Fluticasone furoate 100 μg combined with vilanterol 25 μg (FF/VI)
Number of subjects: 16590
Study: 26520227

Group type: EXPERIMENTAL
Intervention: Mindfulness Therapy for Maladaptive Interpersonal Dependency (MT‐MID)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Minimal contact control
Number of subjects: 48
Study: 23907542

Group type: EXPERIMENTAL
Intervention: Orderly room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disorderly room
Number of subjects: 0
Study: 22224245

Group type: EXPERIMENTAL
Intervention: Neurorehabilitation using stabilizing platforms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computerized dynamic posturography with visual biofeedback
Number of subjects: 0
Study: 19191937

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: General Practitioner (GP)
Number of subjects: 1501
Study: 16317312

Group type: EXPERIMENTAL
Intervention: Risperidone (4.6 mg/day mean dose)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo (previously) then Risperidone
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 283
Study: 15271001

Group type: EXPERIMENTAL
Intervention: Induction task for 5-year-olds
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Training 5-year-olds to perform induction in an adultlike manner
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adults performing induction task
Number of subjects: 50
Study: 10853624

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-question global assessment
Number of subjects: 0
Study: 9313875

Group type: EXPERIMENTAL
Intervention: High-dose melphalan and autograft
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Melphalan or busulfan alone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sequential therapy package including IFN
Number of subjects: 195
Study: 8313405

Group type: EXPERIMENTAL
Intervention: 0.2 mg of nifedipine (Group II)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Solvent (Group I)
Number of subjects: 18
Study: 3104433

Group type: EXPERIMENTAL
Intervention: Nimodipine 1.0 microgram X kg‐1 X min‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nifedipine 0.7 microgram X kg‐1 X min‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) 0.5 microgram X kg‐1 X min‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study: 31718940

Group type: EXPERIMENTAL
Intervention: molecular quantitative trait loci (molQTLs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29406179

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 16
Study: 27760081

Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg once daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 24068437

Group type: EXPERIMENTAL
Intervention: Genetic attribution for schizophrenia
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Genetic attribution for bipolar disorder
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Genetic attribution for major depression
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Genetic attribution for affective disorders (bipolar disorder and major depression)
Number of subjects: 149
Study: 23849436

Group type: EXPERIMENTAL
Intervention: Fasting state (clinofibrate 400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fed state (clinofibrate 400 mg)
Number of subjects: 12
Study: 21181364

Group type: EXPERIMENTAL
Intervention: Routine treatment plus simvastatin (group R+S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine treatment (group R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 40
Study: 17428528

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10mg daily for 5 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 16636633

Group type: EXPERIMENTAL
Intervention: Stress-management program (lectures, coping measures, recording sheets, e-mail counseling) for 3 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 12804059

Group type: COMPARATOR
Intervention: 0 mA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1 mA, 0.5 mA, 1.0 mA, 2.0 mA, 3.0 mA for 20 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.5 mA for 40 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4.0 mA for 20 min
Number of subjects: 24
Study: 10343626

Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Propionate (FP) 880 micrograms bid + Intranasal Fluticasone Propionate (FP) 200 micrograms once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled Triamcinolone Acetonide (TAA) 880 micrograms bid + Intranasal Triamcinolone Acetonide (TAA) 220 micrograms once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Propionate (FP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled Triamcinolone Acetonide (TAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal Fluticasone Propionate (FP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (nPL + inhPL)
Number of subjects: 12
Study: 8606898

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT) for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Practice of reaching tasks for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treatment duration (both types)
Number of subjects: 8
Study: 1945978

Group type: EXPERIMENTAL
Intervention: Regimen A (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg + meperidine 1.5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regimen B (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg)
Number of subjects: 10
Study: 7047580

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3, 0.45, or 0.6 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Morphine (10, 15, or 20 mg)
Number of subjects: 97
Study: 30446577

Group type: EXPERIMENTAL
Intervention: 5-star GRIP rated slip resistant footwear
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Waiting list control group (no footwear during trial)
Number of subjects: 4400
Study: 26547513

Group type: EXPERIMENTAL
Intervention: Vortex Blue (VB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: K3XF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reciproc
Number of subjects: 60
Study: 25242220

Group type: EXPERIMENTAL
Intervention: Spatial attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention field and pRF without attention
Number of subjects: 0
Study: 22221140

Group type: EXPERIMENTAL
Intervention: AV608 (NK1R antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 20137767

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200 mg tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monocrixo L.P. 200 mg capsules
Number of subjects: 30
Study: 17700548

Group type: EXPERIMENTAL
Intervention: GRAIDS (Genetic Risk Assessment on the Internet with Decision Support) support
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison (education and mailed guidelines)
Number of subjects: 45
Study: 16199694

Group type: EXPERIMENTAL
Intervention: Oxygen delivery through nasal cannulae with effective FIO2 <0.23
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oxygen delivery through nasal cannulae with effective FIO2 of 0.21
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Room air through nasal cannulae
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oxygen delivery with effective FIO2 <0.23
Number of subjects: 187
Study: 12243129

Group type: EXPERIMENTAL
Intervention: Enhanced lifestyle interventions (EI)
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Minimum intervention (MI)
Number of subjects: 1586
Study: 9990416

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 100
Study: 8295245

Group type: EXPERIMENTAL
Intervention: Clotrimazole 10 mg three times a day
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg per day
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Nystatin 2 million units every 6 hours
Number of subjects: 292

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 292
Study: 3389331

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) at doses of 100, 200, and 300 kcal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 0
Study: 30572528

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) 25 μg/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fentanyl infusion (IV) 25 μg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (TFP and IV)
Number of subjects: 60
Study: 27100286

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL) module
Number of subjects: 99
Study: 24919102

Group type: EXPERIMENTAL
Intervention: Balance training program in public parks (6 weeks, 2 sessions/week, 12 exercises/session, 50 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Balance training program in public parks
Number of subjects: 28
Study: 23151009

Group type: EXPERIMENTAL
Intervention: Integrated working with NHS services
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Care homes working with multiple general practices
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Professional services visiting care homes
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Integration of care services
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Potential for improved quality of care
Number of subjects: 621
Study: 20954214

Group type: EXPERIMENTAL
Intervention: Test formulation of ondansetron (8 mg)
Number of subjects: 25
Study: 18458658

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 64

Group type: COMPARATOR
Intervention: Continuous indomethacin
Number of subjects: 64
Study: 15681957

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a mean rate of 0.17 mug . kg . min
Number of subjects: 60

Group type: COMPARATOR
Intervention: 70% nitrous oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 15829860

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with +2.00 D near addition
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 469